Xeris Biopharma (XERS) Stock: Why It Rose 24% After Earnings

Quick answer

Xeris Biopharma traded at $12.96 at 11:51am ET on Nov 5, 2026, up 23.9% from a $10.46 close, after a third-quarter report in which its main drug nearly doubled its sales and the company raised its outlook for this year and for 2030. Revenue rose 44% to $107.2 million. Recorlev, its treatment for Cushing's syndrome, grew 93% to $71.5 million. Xeris raised its 2026 revenue guide to $395 million to $405 million from $385 million to $390 million, and its 2030 revenue outlook to more than $1 billion from about $750 million. The stock set a 52-week high of $13.74 at 9:35am, while the biotech fund XBI fell 5.3%.

Our view: Bullish through March 1, 2027, about when the fourth-quarter report is due; Xeris reported on Mar 2 this year. The case for the stock: the guide went up by $12.5 million at the midpoint after a quarter that already ran ahead, and it now implies fourth-quarter revenue of $112.5 million to $122.5 million, above the $107.2 million just reported; Recorlev grew 26% from the second quarter to the third, so the growth is still building; and the company is profitable, with $11.3 million of net income and an 88% gross margin, after retiring its 8% 2028 convertible notes in July. The case against: the stock has more than doubled from its 52-week low of $5.25 and RSI(14) reached 75; it now sits within about $2 of the $15 average analyst target; and Gvoke, its glucagon product, fell 14%, which leaves the company more dependent on one drug. We think the case for carries more weight. At $12.96 the company is valued at about six times the midpoint of this year's revenue guide, net of debt and cash, while management now points to more than $1 billion of revenue in 2030 and a raise to the near-term guide gives that claim support. The $15 average analyst target was set before the new outlook. We would move off Bullish if the stock closes below the Nov 4 close it gapped from, if fourth-quarter revenue comes in below the low end implied by the new guide, or if Recorlev revenue falls from its third-quarter level. This is a view on direction over that window, not a recommendation to trade the stock.

Xeris Biopharma daily closing price from Sep 22 to Nov 5, 2026, with the Oct 20 high close, the Nov 4 close before results and the Nov 5 jump marked

Key takeaways

Xeris Biopharma traded at $12.96 at 11:51am ET on Nov 5, 2026, up 23.9% from a $10.46 close, after third-quarter revenue rose 44% to $107.2 million and the company raised its guidance for both 2026 and 2030.
Recorlev, its treatment for Cushing's syndrome, grew 93% to $71.5 million and is now two thirds of revenue, up from $56.8 million in the second quarter.
Xeris raised its 2026 revenue guide to $395 million to $405 million from $385 million to $390 million, and its 2030 revenue outlook to more than $1 billion from about $750 million.
Net income rose to $11.3 million from $0.6 million a year earlier, and adjusted EBITDA reached $30.8 million, as gross margin improved to 88%.
Our view is Bullish through March 1, 2027: the guide went up after a quarter that already beat, Recorlev is still growing fast from one quarter to the next, and the stock trades at about six times this year's revenue guide against a 2030 outlook of more than $1 billion.

Table of contents

Nov 5, 2026: Recorlev nearly doubles and the outlook goes up twice
The numbers
The bull case
The risks
What comes next

Nov 5, 2026: Recorlev nearly doubles and the outlook goes up twice

Xeris closed Nov 4 at $10.46 and released results at 7:00am ET on Nov 5. Premarket trading started near $10.55 and reached $12.56 by 9:25am. The stock opened at $12.51, made its low of $12.32 at 9:30am and its high of $13.74 at 9:35am, a new 52-week high. At 11:51am it was $12.96 on about 5.6 million shares.

What moved it:

Recorlev kept speeding up. Net revenue of $71.5 million was up 93% from a year earlier and up from $56.8 million in the second quarter. Chief executive John Shannon said Recorlev is now on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.
The 2026 guide went up again. The new range of $395 million to $405 million compares with $385 million to $390 million set on Aug 6.
2030 went up by a third. "We are now on a path to reach more than $1 billion in total revenue in 2030," Shannon said, against a prior outlook of about $750 million.
Profit arrived. Net income was $11.3 million, against $0.6 million a year earlier, and adjusted EBITDA rose to $30.8 million from $17.4 million. Earnings of $0.06 a share compared with a consensus of about $0.03.

The move was company news. Biotech stocks fell with the wider market, with XBI down 5.3% and the S&P 500 fund SPY down 3.2% over the same period. The rest of the session's movers are in today's biggest stock moves.

At 11:51am RSI(14) stood at 75, the shares sat 37.1% above their 50-day average and 71.9% above their 200-day average, volume was already 2.5 times its 20-day average, and the stock was 5.3% below the 52-week high it set that morning.

Bar chart of Xeris third-quarter 2026 net revenue by product: Recorlev $71.5 million, Gvoke $21.7 million, Keveyis $13.0 million, royalty and other $1.0 million

The numbers

Measure	Q3 2026	Change from a year earlier
Total revenue	$107.2 million	+44%
Recorlev	$71.5 million	+93%
Gvoke	$21.7 million	-14%
Keveyis	$13.0 million	+9%
Gross margin	88%	from 85%
Adjusted EBITDA	$30.8 million	from $17.4 million

For the first nine months revenue rose 37% to $282.5 million. The nine-month net loss of $17.6 million includes a one-time, non-cash charge of about $30.8 million in the second quarter tied to exchanging its 2028 convertible notes. Xeris ended September with $131.1 million of cash and $189.7 million of long-term debt. Our guide to guidance changes covers why a raise on top of a beat tends to move a stock, and our page on adjusted EBITDA covers what the adjusted figure leaves out.

The bull case

Recorlev is a rare-disease drug with a long runway, and the numbers show the launch is still building rather than leveling off. Its sales added $14.7 million from the second quarter to the third, and the raised guide implies more growth in the fourth. Xeris also has patent news on its side: a third U.S. patent for XP-8121 was granted on Oct 6, expected to run to 2043, and a new Keveyis patent issued on Oct 13 is expected to protect it through at least 2043. The pivotal Phase 3 study of XP-8121, a once-weekly levothyroxine injection, is due to start by the end of 2026. Our page on earnings estimate revisions covers why a guide raise this large usually pulls analyst estimates and targets up behind it, and our page on post-earnings announcement drift covers why the move often continues.

The risks

One drug now carries the story. Recorlev is two thirds of revenue, and Gvoke fell 14%, so any slowdown in Recorlev prescriptions or pricing would show up quickly. XP-8121 is years away: topline data are expected in late 2028 and a possible launch in 2030, so it adds little before then. The stock has already risen from $5.25 at its 52-week low, it trades near the $15 average target and the $16 high, and a gain this fast can fade on any weak day for biotech. Debt of $189.7 million is more than its cash, although the company is now profitable. Our guide to estimating cash runway covers how to judge a balance sheet like this.

What comes next

The fourth-quarter report is expected around March 1, 2027, with 2027 guidance. Before then, watch whether analysts raise targets above $16, whether the stock holds above the $10.46 close it gapped from, and the start of the XP-8121 Phase 3 study by year end. Fourth-quarter revenue below $112.5 million or a drop in Recorlev sales would undercut the Bullish case.

Frequently asked questions

Why did Xeris Biopharma stock rise on Nov 5, 2026?

Xeris rose 23.9% to $12.96 at 11:51am ET on Nov 5 after its third-quarter report. Revenue rose 44% to $107.2 million, Recorlev sales grew 93% to $71.5 million, and the company raised its 2026 revenue guide to $395 million to $405 million and its 2030 outlook to more than $1 billion. The stock set a 52-week high of $13.74 at 9:35am.

What is Recorlev?

Recorlev (levoketoconazole) is Xeris's treatment for endogenous Cushing's syndrome, a hormone disorder. It made $71.5 million of net revenue in the third quarter of 2026, up 93% from a year earlier, and chief executive John Shannon said it is on a path to nearly $1 billion in annual net revenue three to four years sooner than the company expected.

What is Xeris's guidance for 2026?

Xeris expects 2026 total revenue of $395 million to $405 million, up from $385 million to $390 million set in August. With $282.5 million of revenue in the first nine months, the new range implies fourth-quarter revenue of about $112.5 million to $122.5 million.

What is XP-8121?

XP-8121 is a once-weekly injectable form of levothyroxine for hypothyroidism. Xeris expects its pivotal Phase 3 study to start by the end of 2026, with topline data in late 2028 and a possible launch in 2030.

What is Dombey's view on Xeris Biopharma stock?

Bullish through March 1, 2027, about when its fourth-quarter report is due; it reported on Mar 2 this year. We would move off Bullish if the stock closes below $10.46, the Nov 4 close, if fourth-quarter revenue comes in below the implied $112.5 million low end, or if Recorlev revenue falls from the third quarter's $71.5 million. This is a view on direction over that window, not a recommendation to trade the stock.

Sources

Article details

By James Whitfield, Head of Equity Research, Dombey Capital

Published November 5, 2026 · 5 min read · Event-Driven Investing